A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients
Condition(s):Hepatocellular CarcinomaLast Updated:March 16, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Hepatocellular CarcinomaLast Updated:March 16, 2022Recruiting
Condition(s):NF1; Low-grade GliomaLast Updated:March 15, 2024Recruiting
Condition(s):Melanoma; Squamous Cell Carcinoma of the Head and Neck; Squamous Cell Carcinoma of the Skin; Sarcoma of the Skin; Basal Cell Cancer of the Skin; Breast CancerLast Updated:January 23, 2018Terminated
Condition(s):B Cell Lymphoma; T Cell LymphomaLast Updated:July 20, 2011Terminated
Condition(s):Healthy VolunteersLast Updated:August 13, 2012Completed
Condition(s):HIV-1 Infected Adults With Chronic HIV-1 InfectionLast Updated:March 13, 2018Completed
Condition(s):Brain TumorsLast Updated:June 12, 2023Completed
Condition(s):Glioblastoma Multiforme; Glioblastoma, Adult; Glioma of Brain; Glioblastoma Multiforme of BrainLast Updated:December 27, 2022Active, not recruiting
Condition(s):Low-Grade B-cell LymphomaLast Updated:September 22, 2022Completed
Condition(s):MelanomaLast Updated:October 2, 2015Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.